Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer’s Disease Spectrum with Amyloid PET Imaging-Reference-Cited by-同舟云学术

Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer’s Disease Spectrum with Amyloid PET Imaging

Published:2020-06-02 Issue:3 Volume:75 Page:949-958
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Lim Ho Jae¹,Park Jung Eun¹²,Kim Byeong C.³,Choi Seong-Min³,Song Min-Kyung³,Cho Soo Hyun³,Seo Hyeon Jeong³,Kim Jahae⁴,Song Ho-Chun⁴,Choi Kyu Yeong⁵,Lee Jang Jae⁵,Kim Hoo-Won⁶,Ha Jung-Min⁷,Song Woo Keun⁸,Park Sung-Gyoo⁸,Lee Jung Sup¹²,Lee Kun Ho¹⁵⁹

Affiliation:

1. Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea

2. BK21-plus Research Team for Bioactive Control Technology, Chosun University, Gwangju, Republic of Korea

3. Department of Neurology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea

4. Department of Nuclear Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea

5. Gwangju Alzheimer’s Disease and Related Dementias Cohort Center, Chosun University, Gwangju, Republic of Korea

6. Department of Neurology, Chosun University School of Medicine, Gwangju, Republic of Korea

7. Department of Nuclear Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea

8. Department of Life Science, Bioimaging and Cell Dynamics Research Center, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea

9. Department of Neural Development and Disease, Korea Brain Research Institute, Daegu, Republic of Korea

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference34 articles.

1. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Sperling;Alzheimers Dement,2011

2. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers;Jack;Lancet Neurol,2013

3. Dementia: What pharmacists need to know;Duong;Can Pharm J (Ott),2017

4. A review of fluid biomarkers for Alzheimer’s disease: Moving from CSF to blood;Blennow;Neurol Ther,2017

5. Targeting neuroinflammation in Alzheimer’s disease;Bronzuoli;J Inflamm Res,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early onset diagnosis in Alzheimer’s disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid;Nature Communications;2024-02-02

2. Pioneering the Early Diagnosis of Alzheimer’s Disease: Aβ Oligomers-Sensing Probe for Cerebrospinal Fluid Analysis in Patients;2023-03-27

3. Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer’s Disease Correlated with Choroidal Thickness;International Journal of Molecular Sciences;2023-01-30

4. Diagnostic Blood Biomarkers in Alzheimer’s Disease;Biomedicines;2022-01-13

5. An Optimized Decision Tree with Genetic Algorithm Rule-Based Approach to Reveal the Brain’s Changes During Alzheimer’s Disease Dementia;Journal of Alzheimer's Disease;2021-12-07